Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter Combined Phase 2a/2b Study to Assess the Efficacy and Safety of BAY 1817080 in Patients With Diabetic Neuropathic Pain

NCT04641273 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT04641273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04641273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter Combined Phase 2a/2b Study to Assess the Efficacy and Safety of BAY 1817080 in Patients With Diabetic Neuropathic Pain
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Terminated
Start date
January 22, 2021
Completion date
October 18, 2021
Enrollment
154 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

neuropathic pain associated with diabetic peripheral neuropathy